ALX Oncology Holdings Inc. (ALXO): Price and Financial Metrics


ALX Oncology Holdings Inc. (ALXO): $78.78

1.41 (+1.82%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ALXO Stock Price Chart Interactive Chart >

Price chart for ALXO

ALXO Price/Volume Stats

Current price $78.78 52-week high $117.45
Prev. close $77.37 52-week low $32.51
Day low $76.72 Volume 66,345
Day high $78.93 Avg. volume 245,526
50-day MA $67.80 Dividend yield N/A
200-day MA $69.64 Market Cap 3.18B

ALX Oncology Holdings Inc. (ALXO) Company Bio


ALX Oncology Holdings, Inc. operates as a clinical stage company, which engages in the research and development of therapies for cancer patients. Its objective is to provide clinical therapies for the treatment of myelodysplastic syndromes, acute myeloid leukemia, and a range of solid tumor indications. The company was founded by Corey Goodman, Jaume Pons, and K. Christopher Garcia on April 1, 2020 and is headquartered in Burlingame, CA.


ALXO Latest News Stream


Event/Time News Detail
Loading, please wait...

ALXO Latest Social Stream


Loading social stream, please wait...

View Full ALXO Social Stream

Latest ALXO News From Around the Web

Below are the latest news stories about Alx Oncology Holdings Inc that investors may wish to consider to help them evaluate ALXO as an investment opportunity.

ALX Oncology Announces Initiation of Investigator-Sponsored Trial of Evorpacept (ALX148) in Patients with Indolent and Aggressive Non-Hodgkin Lymphoma

-- Phase 1/2 study conducted at The University of Texas M.D. Anderson Cancer CenterBURLINGAME, Calif., Sept. 16, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the initiation of a Phase 1/2 investigator-sponsored trial of evorpacept (also known as ALX148), a next generation CD47 blocker, in combination with rituximab and lenalidomide for the

Yahoo | September 16, 2021

Lightstone Ventures Raises $375 Million Fund

Lightstone Ventures today announced the closing of Lightstone Ventures III with $375 million in capital commitments, to invest in early-stage companies developing high impact therapeutics and technologies that have the potential to change patients' lives. The new fund was oversubscribed, exceeding the firm's targeted raise, and included strong support from both new and existing limited partners. With the closing of Fund III, Lightstone Ventures also announced the appointments of Christina Isacso

Yahoo | September 14, 2021

ALX Oncology Announces Upcoming Virtual Investor Conference Participation

BURLINGAME, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (ALX Oncology) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that Jaume Pons, Ph.D., Founder, President and Chief Executive Officer and other senior executives, will participate in two upcoming virtual investor conferences.

Intrado Digital Media | September 7, 2021

The 3 Best Biotech Stocks to Buy Right Now

Investing in biotech companies is hard. Shareholders are often subject to wild price swings based on results that may not translate to future studies. ALX Oncology (NASDAQ: ALXO), Vertex Pharmaceuticals (NASDAQ: VRTX), and Beam Therapeutics (NASDAQ: BEAM) are at different stages of the company lifecycle.

Yahoo | August 27, 2021

ALX Oncology Reports Second Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights

BURLINGAME, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the second quarter ended June 30, 2021 and provided clinical development and operational highlights. “We are pleased to report on the substantial progress we made since the prior quarter with our lead product candidate, ALX148, and that the United

Yahoo | August 12, 2021

Read More 'ALXO' Stories Here

ALXO Price Returns

1-mo 5.83%
3-mo 37.63%
6-mo 19.73%
1-year 100.51%
3-year N/A
5-year N/A
YTD -8.61%
2020 N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.3358 seconds.